About all

Trazadone ed. Trazodone for Erectile Dysfunction: A Comprehensive Analysis of Efficacy and Safety

by alexxlab

How effective is trazodone in treating erectile dysfunction. What are the potential benefits and risks of using trazodone for ED. Is trazodone a viable alternative to other ED medications.

Understanding Trazodone and Its Potential Role in Treating Erectile Dysfunction

Trazodone, primarily known as an antidepressant, has garnered attention for its potential use in treating erectile dysfunction (ED). This comprehensive analysis delves into the efficacy and safety of trazodone as a treatment option for men struggling with ED, based on a systematic review and meta-analysis of available clinical data.

What is Trazodone?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) primarily used to treat depression and anxiety disorders. Its potential benefits for erectile dysfunction have been a subject of interest in recent years, prompting researchers to investigate its efficacy in this off-label use.

The Scope and Methodology of the Trazodone ED Study

The systematic review and meta-analysis aimed to evaluate the effectiveness and safety of trazodone in treating erectile dysfunction. Researchers conducted a thorough examination of available literature, focusing on randomized controlled trials that met specific criteria.

Study Selection Criteria

  • Inclusion of men with erectile dysfunction
  • Comparison of trazodone with a control group
  • Randomized study design
  • Minimum duration of 7 days
  • Assessment of clinically relevant outcomes

The research team scoured multiple databases, including Medline and the Cochrane Library, covering publications from January 1966 to May 2002. They also examined bibliographies of retrieved articles, review articles, and relevant conference proceedings and abstracts to ensure a comprehensive analysis.

Key Findings from the Trazodone ED Meta-Analysis

The meta-analysis included six trials, encompassing a total of 396 men. While the studies provided valuable insights, it’s important to note that they exhibited heterogeneity in population characteristics and some methodological limitations.

Efficacy of Trazodone for ED

Three out of the six trials demonstrated a clinically meaningful benefit of trazodone for erectile dysfunction compared to placebo. In two of these trials, the differences were statistically significant. When pooling the results, trazodone monotherapy appeared more likely than placebo to lead to a ‘positive treatment response’, although the difference did not reach statistical significance (37% vs 20%; relative benefit increase, 1.6; 95% confidence interval, CI, 0.8-3.3).

Subgroup Analysis: Psychogenic vs. Physiological ED

Interestingly, the analysis suggested that men with psychogenic erectile dysfunction might be more likely to benefit from trazodone compared to those with mixed or physiological ED. This finding highlights the potential importance of considering the underlying cause of ED when evaluating treatment options.

Dosage Considerations

The efficacy of trazodone appeared to be dose-dependent, with higher doses (150-200 mg/day) showing greater effectiveness compared to lower doses (50 mg/day). This observation underscores the importance of appropriate dosing in maximizing the potential benefits of trazodone for ED.

Safety Profile and Tolerability of Trazodone in ED Treatment

When evaluating any medication for off-label use, safety is a paramount concern. The meta-analysis provided insights into the tolerability of trazodone when used for erectile dysfunction.

Withdrawal Rates

The study found that men randomized to trazodone were not significantly more likely to withdraw from the trials compared to those receiving placebo. This suggests that trazodone was generally well-tolerated in the context of ED treatment.

Common Side Effects

While the meta-analysis did not provide an exhaustive list of side effects, it’s important to note that trazodone, like any medication, can cause adverse reactions. Common side effects of trazodone may include:

  • Drowsiness
  • Dizziness
  • Dry mouth
  • Blurred vision
  • Constipation

It’s crucial for patients considering trazodone for ED to discuss potential side effects and drug interactions with their healthcare provider.

Comparing Trazodone to Other ED Treatments

While the meta-analysis focused specifically on trazodone, it’s important to consider how it compares to other established treatments for erectile dysfunction.

Trazodone vs. PDE5 Inhibitors

Phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), are the most commonly prescribed medications for ED. These drugs have undergone extensive clinical trials and have demonstrated significant efficacy in treating erectile dysfunction.

Does trazodone offer any advantages over PDE5 inhibitors? While trazodone may be beneficial for some patients, particularly those with psychogenic ED, it has not shown the same level of consistent efficacy as PDE5 inhibitors in treating erectile dysfunction across various patient populations.

Potential Niche for Trazodone in ED Treatment

Despite not being as broadly effective as PDE5 inhibitors, trazodone may have a role in specific scenarios:

  1. Patients with contraindications to PDE5 inhibitors
  2. Men with concurrent depression and ED
  3. Cases where psychogenic factors are the primary cause of ED

In these situations, trazodone might offer a viable alternative or complementary treatment option.

Limitations of the Trazodone ED Meta-Analysis

While the systematic review and meta-analysis provide valuable insights, it’s important to acknowledge the limitations of the study:

  • Small sample sizes in individual trials
  • Heterogeneous patient populations
  • Short duration of most studies
  • Methodological weaknesses in some trials
  • Limited data on long-term efficacy and safety

These limitations highlight the need for larger, more robust clinical trials to further evaluate the efficacy and safety of trazodone for erectile dysfunction.

Future Directions in Trazodone ED Research

The findings of this meta-analysis open up several avenues for future research in the use of trazodone for erectile dysfunction:

Large-Scale Clinical Trials

Conducting larger, well-designed randomized controlled trials with diverse patient populations would provide more definitive evidence on the efficacy of trazodone for ED.

Long-Term Safety and Efficacy Studies

Investigating the long-term effects of trazodone use for ED, including potential side effects and sustained efficacy, is crucial for establishing its viability as a treatment option.

Comparative Studies

Direct comparisons between trazodone and established ED treatments, such as PDE5 inhibitors, would help clarify its relative efficacy and identify specific patient groups who might benefit most from trazodone therapy.

Mechanism of Action Research

Further investigation into the precise mechanisms by which trazodone may improve erectile function could lead to the development of more targeted therapies or combination treatments.

As research in this area continues, healthcare providers and patients alike will benefit from a more comprehensive understanding of trazodone’s potential role in managing erectile dysfunction. While the current evidence suggests some promise, particularly for certain subgroups of patients, more robust data is needed to definitively establish trazodone’s place in the ED treatment landscape.

In conclusion, the systematic review and meta-analysis of trazodone for erectile dysfunction provide a foundation for understanding its potential benefits and limitations. As with any medical treatment, patients considering trazodone for ED should consult with their healthcare provider to discuss the most appropriate options based on their individual health profile, preferences, and the latest available evidence.

Trazodone for erectile dysfunction: a systematic review and meta-analysis

Save citation to file

Format:

Summary (text)PubMedPMIDAbstract (text)CSV

Add to Collections

  • Create a new collection
  • Add to an existing collection

Name your collection:

Name must be less than 100 characters

Choose a collection:

Unable to load your collection due to an error
Please try again

Add to My Bibliography

  • My Bibliography

Unable to load your delegates due to an error
Please try again

Your saved search

Name of saved search:

Search terms:

Test search terms

Email:

(change)

Which day?

The first SundayThe first MondayThe first TuesdayThe first WednesdayThe first ThursdayThe first FridayThe first SaturdayThe first dayThe first weekday

Which day?

SundayMondayTuesdayWednesdayThursdayFridaySaturday

Report format:

SummarySummary (text)AbstractAbstract (text)PubMed

Send at most:

1 item5 items10 items20 items50 items100 items200 items

Send even when there aren’t any new results

Optional text in email:

Create a file for external citation management software

Review

. 2003 Sep;92(4):441-6.

doi: 10.1046/j.1464-410x.2003.04358.x.

H A Fink 
1
, R MacDonald, I R Rutks, T J Wilt

Affiliations

Affiliation

  • 1 Geriatric Research Education and Clinical Center, Section of General Internal Medicine, VA Medical Center, Minneapolis, USA. [email protected]

  • PMID:

    12930437

  • DOI:

    10.1046/j.1464-410x.2003.04358.x

Review

H A Fink et al.

BJU Int.

2003 Sep.

. 2003 Sep;92(4):441-6.

doi: 10. 1046/j.1464-410x.2003.04358.x.

Authors

H A Fink 
1
, R MacDonald, I R Rutks, T J Wilt

Affiliation

  • 1 Geriatric Research Education and Clinical Center, Section of General Internal Medicine, VA Medical Center, Minneapolis, USA. [email protected]

  • PMID:

    12930437

  • DOI:

    10.1046/j.1464-410x.2003.04358.x

Abstract


Objective:

To determine the efficacy and safety of trazodone in the treatment of erectile dysfunction (ED) in a meta-analysis.


Methods:

The data sources used were Medline and the Cochrane Library databases (January 1966 to May 2002), bibliographies of retrieved articles and review articles, and conference proceedings and abstracts. Trials were eligible for inclusion in the review if they included men with ED, compared trazodone with a control, were randomized, of > or = 7 days’ duration and assessed clinically relevant outcomes. Two reviewers independently evaluated study quality and extracted data in a standardized fashion.


Results:

Six trials (comprising 396 men) met the inclusion criteria; they consisted of heterogeneous populations, were small, brief and in some cases methodologically weak. Three of the six trials showed an apparently clinically meaningful benefit of trazodone for ED compared with placebo, the differences being statistically significant in two. In pooled results, trazodone monotherapy appeared more likely than placebo to lead to a ‘positive treatment response’, although this difference was not statistically significant (37% vs 20%; relative benefit increase, 1.6; 95% confidence interval, CI, 0.8-3.3). Subgroup analyses suggested that men with psychogenic ED might be more likely to benefit from trazodone than those with mixed or physiological ED. The efficacy of trazodone also appeared greater at higher doses (150-200 vs 50 mg/day). Men randomized to trazodone were not significantly more likely than those receiving placebo to withdraw for any reason or for an adverse event, or to have specific adverse events, but wide CIs could not exclude a greater risk of these adverse outcomes with trazodone. Specific adverse events with trazodone included dry mouth (19%), sedation (16%), dizziness (16%) and fatigue (15%).


Conclusion:

Trazodone may be helpful in men with ED, possibly more so at higher doses, and in men with psychogenic ED. Future high-quality trials should compare trazodone with placebo and other therapies in men with depression and psychogenic ED.

Similar articles

  • Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.

    Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ.

    Fink HA, et al.
    Arch Intern Med. 2002 Jun 24;162(12):1349-60. doi: 10.1001/archinte.162.12.1349.
    Arch Intern Med. 2002.

    PMID: 12076233

    Review.

  • Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings.

    Enzlin P, Vanderschueren D, Bonte L, Vanderborght W, Declercq G, Demyttenaere K.

    Enzlin P, et al.
    Int J Impot Res. 2000 Aug;12(4):223-8. doi: 10.1038/sj. ijir.3900550.
    Int J Impot Res. 2000.

    PMID: 11079363

    Clinical Trial.

  • Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.

    Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G.

    Markou S, et al.
    Int J Impot Res. 2004 Dec;16(6):470-8. doi: 10.1038/sj.ijir.3901258.
    Int J Impot Res. 2004.

    PMID: 15229625

    Review.

  • Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.

    Stridh A, Pontén M, Arver S, Kirsch I, Abé C, Jensen KB.

    Stridh A, et al.
    JAMA Netw Open. 2020 Mar 2;3(3):e201423. doi: 10.1001/jamanetworkopen.2020.1423.
    JAMA Netw Open. 2020.

    PMID: 32196105
    Free PMC article.

  • A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study.

    Taneja R.

    Taneja R.
    J Sex Med. 2007 Jul;4(4 Pt 2):1136-41. doi: 10.1111/j.1743-6109.2007.00507.x. Epub 2007 May 2.
    J Sex Med. 2007.

    PMID: 17484772

    Clinical Trial.

See all similar articles

Cited by

  • Erectile Dysfunction: Treatments, Advances and New Therapeutic Strategies.

    Argiolas A, Argiolas FM, Argiolas G, Melis MR.

    Argiolas A, et al.
    Brain Sci. 2023 May 15;13(5):802. doi: 10.3390/brainsci13050802.
    Brain Sci. 2023.

    PMID: 37239274
    Free PMC article.

    Review.

  • Individual and simultaneous treatment with antipsychotic aripiprazole and antidepressant trazodone inhibit sterol biosynthesis in the adult brain.

    Balog M, Anderson A, Genaro-Mattos TC, Korade Z, Mirnics K.

    Balog M, et al.
    J Lipid Res. 2022 Aug;63(8):100249. doi: 10.1016/j.jlr.2022.100249. Epub 2022 Jul 14.
    J Lipid Res. 2022.

    PMID: 35839864
    Free PMC article.

  • Core-shell particles and monolithic columns; tools for simultaneous LC analysis of avanafil, sildenafil, apomorphine, trazodone, yohimbine, tramadol and dapoxetine in pharmaceutical dosage forms, counterfeit products and human plasma.

    Ibrahim AE, Hashem H, Elhenawee M, Saleh H.

    Ibrahim AE, et al.
    RSC Adv. 2020 Jan 8;10(3):1379-1387. doi: 10.1039/c9ra08717f. eCollection 2020 Jan 7.
    RSC Adv. 2020.

    PMID: 35494721
    Free PMC article.

  • Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer.

    Liu JM, Shen CY, Lau WCY, Shao SC, Man KKC, Hsu RJ, Wu CT, Lai EC.

    Liu JM, et al.
    Cancers (Basel). 2021 Jul 31;13(15):3861. doi: 10.3390/cancers13153861.
    Cancers (Basel). 2021.

    PMID: 34359762
    Free PMC article.

  • Treatments of Sexual Dysfunction in Opioid Substitution Therapy Patients: A Systematic Review and Meta-Analysis.

    Ramli FF, Azizi MH, Syed Hashim SA.

    Ramli FF, et al.
    Int J Med Sci. 2021 Apr 12;18(11):2372-2380. doi: 10.7150/ijms.57641. eCollection 2021.
    Int J Med Sci. 2021.

    PMID: 33967614
    Free PMC article.

See all “Cited by” articles

Publication types

MeSH terms

Substances

Cite

Format:

AMA

APA

MLA

NLM

Send To

Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review

. 1995 Jul;46(1):117-20.

doi: 10.1016/S0090-4295(99)80176-9.

R Lance 
1
, M Albo, R A Costabile, W D Steers

Affiliations

Affiliation

  • 1 Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA.

  • PMID:

    7604472

  • DOI:

    10.1016/S0090-4295(99)80176-9

R Lance et al.

Urology.

1995 Jul.

. 1995 Jul;46(1):117-20.

doi: 10.1016/S0090-4295(99)80176-9.

Authors

R Lance 
1
, M Albo, R A Costabile, W D Steers

Affiliation

  • 1 Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA.

  • PMID:

    7604472

  • DOI:

    10.1016/S0090-4295(99)80176-9

Abstract


Objectives:

Anecdotal reports of increased libido and sexual function in patients taking trazodone have led to its empirical use in patients with erectile dysfunction. A retrospective review of patient-reported responses to trazodone was performed to outline the efficacy and side-effect profile of this agent.


Methods:

Between 1989 and 1994, 182 patients were placed on oral trazodone as empirical therapy for erectile dysfunction. Patients ranged in age from 26 to 85 years, with a mean of 60 years. Patients were evaluated before receiving trazodone with a thorough medical history and physical examination. Known risk factors for erectile dysfunction were assigned based on historical information and the findings of the examination. Patients received trazodone for at least 2 consecutive months, with daily doses starting at 25 mg.


Results:

One hundred twenty-seven patients were available for follow-up by a standardized questionnaire regarding perceived improvement in erectile function, sexual function, and side effects. In patients less than 60 years of age, with no known risk factors for erectile dysfunction, 21 of 27 (78%) showed significant improvement in erectile ability. Smokers and patients older than 60 years with a history of significant peripheral vascular disease responded poorly to trazodone therapy. The duration of erectile dysfunction was inversely related to a response to trazodone. Of patients with a duration of impotence less than 12 months, 48% reported a positive response. Only 16% of patients with duration of erectile dysfunction greater than 60 months reported improvement in erections and sexual function. Trazodone was well tolerated by this population, with 62% reporting no side effects.


Conclusions:

Despite the limitations of a nonrandomized, retrospective study, trazodone appears to benefit younger patients with erectile dysfunction with few known risk factors. A prospective, placebo-controlled trial is needed to confirm the observations of this pilot study.

Similar articles

  • Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial.

    Costabile RA, Spevak M.

    Costabile RA, et al.
    J Urol. 1999 Jun;161(6):1819-22.
    J Urol. 1999.

    PMID: 10332444

    Clinical Trial.

  • A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma.

    Incrocci L, Slagter C, Slob AK, Hop WC.

    Incrocci L, et al.
    Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):439-44. doi: 10.1016/j.ijrobp.2006.04.047.
    Int J Radiat Oncol Biol Phys. 2006.

    PMID: 16965992

    Clinical Trial.

  • Treatment of erectile dysfunction in patients with Peyronie’s disease using sildenafil citrate.

    Levine LA, Latchamsetty KC.

    Levine LA, et al.
    Int J Impot Res. 2002 Dec;14(6):478-82. doi: 10.1038/sj.ijir.3900912.
    Int J Impot Res. 2002.

    PMID: 12494281

  • Trazodone for erectile dysfunction: a systematic review and meta-analysis.

    Fink HA, MacDonald R, Rutks IR, Wilt TJ.

    Fink HA, et al.
    BJU Int. 2003 Sep;92(4):441-6. doi: 10.1046/j.1464-410x.2003.04358.x.
    BJU Int. 2003.

    PMID: 12930437

    Review.

  • Physical activity and erectile dysfunction in middle-aged men.

    La Vignera S, Condorelli R, Vicari E, D’Agata R, Calogero AE.

    La Vignera S, et al.
    J Androl. 2012 Mar-Apr;33(2):154-61. doi: 10.2164/jandrol.111.013649. Epub 2011 May 19.
    J Androl. 2012.

    PMID: 21597089

    Review.

See all similar articles

Cited by

  • Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

    Nguyen CT, MacEntee MI, Mintzes B, Perry TL.

    Nguyen CT, et al.
    Drugs Aging. 2014 Jan;31(1):55-65. doi: 10.1007/s40266-013-0141-5.
    Drugs Aging. 2014.

    PMID: 24293180

  • Future prospects in the treatment of erectile dysfunction: focus on avanafil.

    Alwaal A, Al-Mannie R, Carrier S.

    Alwaal A, et al.
    Drug Des Devel Ther. 2011;5:435-43. doi: 10.2147/DDDT.S15852. Epub 2011 Oct 18.
    Drug Des Devel Ther. 2011.

    PMID: 22087063
    Free PMC article.

    Review.

  • Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

    Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brullé C, Bouchard S, Rozova A.

    Sheehan DV, et al.
    Psychiatry (Edgmont). 2009 May;6(5):20-33.
    Psychiatry (Edgmont). 2009.

    PMID: 19724732
    Free PMC article.

  • Looking to the future for erectile dysfunction therapies.

    Hatzimouratidis K, Hatzichristou DG.

    Hatzimouratidis K, et al.
    Drugs. 2008;68(2):231-50. doi: 10.2165/00003495-200868020-00006.
    Drugs. 2008.

    PMID: 18197727

    Review.

  • Pharmacologic treatment of erectile dysfunction.

    Steers WD.

    Steers WD.
    Rev Urol. 2002;4 Suppl 3(Suppl 3):S17-25.
    Rev Urol. 2002.

    PMID: 16986010
    Free PMC article.

See all “Cited by” articles

MeSH terms

Substances

Treatment of erectile dysfunction and lower urinary tract syndrome in Butovo in the high-tech clinic “LazerVita”

Modern approach to the treatment of erectile dysfunction and lower urinary tract syndrome caused by stressful conditions

Gnoyan Sergey Vasilievich urologist andrologist

During the year, 23 patients came to our clinic with complaints of a decrease in copulative function that occurred after a stressful state. The age of the patients ranged from 31 to 56 years. 14 (60.9%) of patients over 40 years of age had lower urinary tract syndrome (dissatisfaction with urination). Initially, the patients were prescribed DNA PCR analysis for 15 STIs, microscopic analysis of pancreatic secretion. According to preliminary analyzes: Ureaplasma urealyticum + Gardnerella vaginalis was detected in 10 (43.5%) patients. In the analysis of the secretion of the pancreas, leukocytes are 50-70 in the field of view, there are no chimney grains. In 5 (21.7%) patients, the following were detected: Chlamidia trachomatis + Candida albicans. In the analysis of the secret of the pancreas, leukocytes 30-50 in the field of view, lecithin grains – an insufficient amount. In the remaining 8 (34.8%) patients, no pathology was detected in the preliminary tests.

Two groups of patients diagnosed with STIs were previously given a course of antibiotic therapy with a fluoroquinolone drug levofloxacin (Eleflox) 500 mg intravenously in combination with the immunomodulator geneferon in suppositories 1 million IU, 1 suppository at night for 10 days. Then, all patients were prescribed a comprehensive program of drug and physiotherapy treatment. During the treatment, Tada-lafil (Cialis) 5 mg daily for 28 days, trazodone (trittiko) 75 mg daily for 28 days, sperm-strong (BAA) 1 capsule daily 2 times a day for 28 days were prescribed. The entire group of patients underwent a course of treatment with local negative pressure (LOP-therapy) using the AMVL-01 “Yarovit” device with a daily selection of an individual treatment program. Also, all patients underwent a 10-day course of laser therapy with the Mustang-2000 apparatus. Rectal and surface sensors were used simultaneously.

At the end of the course of LOD-therapy and laser therapy, a 10-day course of intravenous ozone therapy was carried out in combination with intravenous laser blood irradiation. Against the background of the entire course of therapy every other day, patients underwent pancreatic massage and intramuscular administration of the drug prostatilen. At the end of the treatment, 20 (87%) patients did not show any complaints. Two (9%) patients felt insecure before sexual intercourse. They continued maintenance therapy with tada-lafil (Cialis) 5 mg + trazodone (Trittico) 75 mg for another 28 days. During the next calendar year, this group of patients did not complain. Thus, this complex treatment allows patients to avoid recurrence of the disease for a long time.

The article was published in the collection of abstracts of the First Russian-Asian Congress, held in St. Petersburg from May 24 to May 26, 2014.

Erectile dysfunction in diabetic patients | Buziashvili

1. Kozlov G.I. // Modern concepts of clinical endocrinology. Materials of the 1st Moscow Congress of Endocrinologists. – M., 1997. -S. 179-185.

2. Aggour A., ​​Mostafa H., el-Shawaf H. // Int. Urol. Nephrol. – 1998. – Vol. 30, N. 1. – P. 75-79.

3. Bar-Moshe O., Vandendris M.//J.Urol.- 1988.- Vol. 1 39. – P. 12171219.

4. Baskin H.J. // South. Med. J. – 1989. – Vol. 82, N. 4. – P. 446-449.

5. Bejany D.E., Perito P.E., Lustgarten M., Rhamy R.K. // J. Urol. – 1993. – Vol. 150.-p. 190-191.

6. Benvenuti F., Boncinelli L., Vignoli G.C. // Neurourol. Urodyne. – 1993. – Vol. 12. – P. 145-151.

7. Bhasin S., Bagatell C.J., BremnerW.J., et al. // J. Clin. Endocrinol. Metab. – 1998. – Vol. 83, N. 10. – P. 3435-3448.

8. Bredt D.S., Hwang P.M., Snyder S.H. // Nature. – 1990. – Vol. 347. – P. 768-770.

9. Brindley G.S. // Br. J Pharmacol. – 1986. – Vol. 87. – P. 495-500.

10. Carani C., Granata A.R., Bancroft J., Marrama P. // Psychoneuroendocrinology. – 1995. – Vol. 20, N. 7. – P. 743-753.

11. Chang T.C., Tung C.C., Hsiao Y.L. // Gerontology. – 1994. – Vol. 40, N.5. – P. 260-267.

12. Cunningham M.J., Clifton D.K., Steiner R.A. // Biol. reproduction. – 1999. – Vol. 60.-p. 216-222.

13. DeGroat W.C., Steers W.D. // Contemporary Management of Impotence and Infertility. – Baltimore, 1988. – P. 3-27.

14. Djamilian M. H., Truss M.C., Tan H.K., et al. // Ann. Urol. (Paris). – 1993. -Vol. 27, N. 3.-P. 136-143.

15. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. // J. Urol. – 1994. -Vol. 151. – P. 54-61.

16. Francavilla S., Properzi G., Bellini C., et al. // J. Urol. – 1997. – Vol. 158, N. 5.-P. 1770-1774.

17. Geisser M.E., Murray F.T., Cohen M.S., et al. // J. Androl. – 1993. – Vol. 14, N. 4. – P. 298-303.

18. Georgitis W.J., Merenich J.A. // Diabetes Care. – 1995. – Vol. 1 8, N. 3. – P. 345-352.

19. Guay A.T., Heatley G.J., Murray F.T. // Urology. – 1996. – Vol. 48. – P. 912-916.

20. Guay A.T. // Diabetes Spectrum. – 1998. – Vol. 1 1, N. 2. – P. 101-111.

21. Hakim L.S., Goldstein I. // Endocrinol. Metab. Clin. North Am. – 1996. – Vol. 25.-P. 379-400.

22. Hakim L.S., Munarriz R.M., Kulaksizoglu H., et al. // J. Urol. – 1996. – Vol. 155. P. 534-535.

23. Hayashi K., Takamizawa K., Nakamura T., et al. // Atherosclerosis. – 1987.-Vol. 66. – P. 259-267.

24. Jenson S.B.// Sex. behavior. – 1986. – Vol. 15. – P. 271-283.

25. Kaiser F.E., Korenman S.G. // Am. J. Med. – 1988. – Vol. 85. – P. 147-152.

26. Kamai T., Fukumoto Y., Gousse A., et al. // J. Urol. – 1994. – Vol. 152. – P. 1017-1021.

27. Kayigil O., Atahan O., Metin A. // Int. Urol. Nephrol. – 1996. – Vol. 28, N. 5.-P. 717-721.

28. Kim S.-C., Ahn S.-Y., Park S.-H., et al. // J. Korean Med. sci. – 1995. – Vol. 10, N. 1,-P. 1-6.

29. Klein R., Klein B.E., Lee K.E., et al. // Diabetes Care. – 1996. – Vol. 19, N. 2.-P. 135-141.

30. Lai S., Tesfaye Y., Thavundayil J.X., et al. // Prog. Neuropsychopharmacol. Biol. Psychiatry. – 1989. – Vol. 13. – P. 329-339.

31. Levine S.B., Fones C.S.L. // Diabetes Rev. 1998.-Vol. 6, N. 1. – P. 41-49.

32. Lugg J.A., Rajfer J., Gonzalez-Cadavid N.F. // endocrinology. – 1995. – Vol. 136, N. 4.-P. 1495-1501.

33. Lustman P.J., Griffith L.S. , Clouse R.E. // Semin. Clin. Neuropsychiatr. – 1997. -Vol. 2, N.l.-P. 15-23.

34. Meinhardt W., Schmitz P.I.M., Kropman R.F., et al. // Int. J. Impot. Res. – 1997. -Vol. 9.-P. 163-165.

35. Miccoli R., Giampietro O., Tognarelli M., et al. // J. Med. 1987. – Vol.18. -P. 305-321.

36. Montorsi F., Guazzoni G., Bergamaschi F., et al. // Acta Diabetol. – 1994. – Vol. 31. – P. 1-5.

37. Mooradian A.D., Morley J.E., Billington C.J., et al. // postgrade. Med. J. – 1985.-Vol. 61.-P. 11-14.

38. Murray F.T., Wyss H.U., Thomas R.G., et al. // J. Clin. Endocrinol. Metab. – 1987. – Vol. 65, N. 1. – P. 127-135.

39. Nadig P.W. // World J. Urol. – 1990. – Vol. 8. – P. 1 14-1 17.

40. National Institutes of Health Consensus Development Panel On Impotence. // JAMA.- 1993.-Vol. 270.-P. 83-90.

41. Nisen H.O., Alfthan O.S., Lindstrom B.L., et al. // Int. J. Impotence Res. – 1990. -Vol. 2, Suppl. 2. – P. 136.

42. O’Hare J.A., Abuaisha F. , Geoghegan M. // Ir. J. Med. sci. – 1994. – Vol. 163.-p. 132-135.

43. Pereira Arias J.G., Escobal Tamayo V., Marana Fernandez M.T., et al. // Arch. Esp. Urol. – 1994. – Vol. 47. N. 7. – P. 703-708.

44. Pfizer Inc. Viagra. Monograph. In Russian. – New York, 1998.

45. Rossi P., Menchini Fabris F., Fiorini I., et al. // Biomed. Pharmacother. – 1998. -Vol. 52, N. 7-8.-P. 308-310

46. Rubin R.R., Peyrot M. // Diabetes Spectrum. – 1998. – Vol. 1 1, N. 2. – P. 81-88.

47. Saenz de Tejada I., Goldstein I. // Urol. Clin. North Am. – 1988. – Vol. 15, N.l.-P. 17-22.

48. Schiavi R.C., White D., Mandeli J., Schreiner-Engel P. // Arch. sex. behavior. – 1993. – Vol. 22, N. 3. – P. 207-215.

49. Schirar A., ​​Chang C., Rousseau J.P. // J. Neuroendocrinol. – 1997. – Vol. 9, N. 2.-P. 141-150.

50. Seethalakshmi L., Menon M., Diamond D. // J. Urol. – 1987. – Vol. 138, N.l.-P. 190-194.

51. Seftel A.D., Vaziri N.D., Ni Z., et al. // Urology. – 1997. Vol. 50, N. 6. – P. 1016-1026.

52. Setter S.M., Baker D.E., Campbell R.K., Johnson S.B. // Diabetes Educ. – 1999. -Vol. 25, N.l.-P. 79-89

53. Seyoum B. // East. Afr. Med. J. – 1998. – Vol. 75, N. 4. – P. 208-210.

54. Shabsigh R. // World J. Urol. – 1997. – Vol. 15, N. 1. – P. 21-26.

55. Susset J.G., Tessier C.D., Wineze J., et al. // J. Urol. – 1989. – Vol. 141.-P. 1360-1363.

56. Tchernof A., Despres J.P., Belanger A., ​​et al. // Metabolism. – 1995. – Vol. 44.-p. 513-519.

57. Tenover J.L. // Endocrinol. Metab. Clin. North. Am. – 1998. – Vol. 27, N. 4. – P. 969-987.

58. Tesfaye S., Stevens L.K., Stephenson J.M., et al. // Diabetology. – 1996.-Vol. 39.-p. 1377-1384.

59. van Ahlen H., Hertle L. // Andrology: male reproductive health and dysfunction. – Berlin, 1997. – P. 173-205.

60. Vardi Y., Sprecher E., Kanter Y., et al. // Int. J. Impot. Res. – 1996. – Vol. 8, N. 2. – P. 65-68.

61. Vernet D.